Diagnostic screening programs help catch cancer, abnormalities or other diseases before they reach an advanced stage, saving lives and healthcare costs. Screening programs include, lung, breast, prostate, and cervical cancer, among many others.
New findings published in RSNA's Radiology highlight the shortcomings of using nodule characteristics and patient history alone to predict an individual’s true cancer risk.
It is estimated that less than 20% of eligible patients in the U.S. adhere to LCS recommendations, despite numerous studies highlighting the exam’s effectiveness.
Chest X-rays could be the key to mitigating the issue of overdiagnosis in certain patient populations undergoing lung cancer screening, according to new research.
Assessing more than 11,000 patients with lesions designated as BI-RADS 4, radiologists using digital breast tomosynthesis found no significant diagnostic advantages over standard 2D mammography.
“These findings emphasize the importance of early recognition of IPV and timely intervention to prevent further harm to the victim,” authors of research published in Academic Radiology cautioned.
Providers screening women with dense breasts and benign breast disease should consider individualized mammogram protocols for these patients, authors of the study suggested.
An international panel of experts recently developed and validated a reporting assessment scoring system that analyzes the location and extent of prostate cancer recurrence.
Outside of the correlation between measurements obtained using both modalities, the researchers also identified Hounsfield unit thresholds that could reliably rule out osteoporosis.
"This awareness is important to avoid oversight of symptoms like dyspnea and vague chest discomfort, which can easily be interpreted as symptoms caused by the known disease COPD,” experts involved in the study said.
Of the 51 plans, just 31% were consistent with the USPSTF recommendations pertaining to the starting age and frequency of screening women who are at average risk of developing breast cancer.